Nubeqa™ (Darolutamide) Gains Third Approval in China for Treatment of Advanced Prostate Cancer in Men The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi)…
Bristol Myers Squibb Launches “Change the Target. Change What’s Possible.” Campaign to Address Unmet Needs in Cardiovascular and Thromboembolic Care Bristol Myers Squibb announced today the launch of “Change the Target.…
Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained and Significant Weight Loss in Phase 2b Trial Pfizer Inc. today announced positive topline results from the Phase 2b VESPER-3 study investigating…
Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in…
Exelixis Announces FDA Acceptance of New Drug Application for Zanzalintinib Combined with Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Exelixis, Inc. today announced that its New Drug Application (NDA) for…
Bio-Techne Broadens 3D Stem Cell and Organoid Culture Offerings with a Fully Defined, Synthetic Matrix Alternative Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic…
Phase 3 Trial of Fezolinetant in Japan Reports Positive Topline Results for Menopausal Vasomotor Symptoms (VMS) Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced topline…
EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio…
Real-World Head-to-Head Analysis Reveals 51% Lower Risk of Death in Metastatic Castration-Sensitive Prostate Cancer Patients Treated with ERLEADA® (Apalutamide) Compared to Darolutamide—Without Docetaxel—Over 24 Months Johnson & Johnson today announced new…
Novo Nordisk A/S: CagriSema Shows Superior HbA1c Reduction of 1.91% and 14.2% Weight Loss in Adults with Type 2 Diabetes in REIMAGINE 2 Trial Novo Nordisk today announced headline results…
Finerenone Recommended in the EU for Heart Failure Patients with LVEF ≥40% Bayer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of…